We verified the reported effects of miR-330-3p on BM of NSCLC [37], and the application of EGFR-targeted drugs—gefitinib and osimertinib in the treatment of NSCLC BM [51, 52]. This evidence concerns the gene EGFR and non-small cell lung carcinoma.